Sustained-Release Injectable Drug Delivery - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Sustained-Release Injectable Drug Delivery
A review on the current status of long-acting injectables, including commercially marketed products. This article is part of a special Drug Delivery issue.


Pharmaceutical Technology
pp. s6-s13

References

1. J. Prettyman, Medsurg Nurs. 14 (2), 93–98 (2005).

2. V.R. Sinha and A. Trehan, J. Control. Release 90 (3), 261–280 (2003).

3. A. Hatefi and B. Amsden, J. Control. Release 80 (1–3), 9–28 (2002).

4. C.B. Packhaeuser et al., Eur. J. Pharm. Biopharm. 58 (2), 445–455 (2004).

5. D. Chitkara et al., Macromol. Biosci. 6 (12), 977–990 (2006).

6. H.M. Mansour et al., Int. J. Mol. Sci. 11 (9), 3298–3322 (2010).

7. A. Jostel and S.M. Shalet, Treat. Endocrinol. 5 (3), 139–145 (2006).

8. Y. Capan et al., AAPS PharmSciTech 4 (2), E28 (2003).

9. Z.H. Gao et al., Peptides 30 (10), 1874–1881 (2009).

10. B.H. Woo et al., Pharm. Res. 18 (12), 1747–1553 (2001).

11. S. Giovagnoli et al. AAPS PharmSciTech 5 (4), Article 51 (2004).

12. B.A. Dani and P.P. DeLuca, AAPS PharmSciTech 2 (4), 22 (2001).

13. B.A. Dani et al., AAPS PharmSciTech 3 (3), E21-end page (2002).

14. P.C. Naha, V. Kanchan, and A.K. Panda, J. Biomater. Appl. 24 (4), 309–325 (2009).

15. D.B. Shenoy et al. Drug Dev. Ind. Pharm. 29 (5), 555–563 (2003).

16. G. Jiang, W. Qiu, and P.P. DeLuca, Pharm. Res. 20 (3), 452–459 (2003).

17. Y. Capan et al., J. Control. Release 60 (2–3), 279–286 (1999).

18. Y. Capan et al., Pharm. Res. 16 (4), 509–513 (1999).

19. S. Gebrekidan, B.H. Woo, and P.P. DeLuca, AAPS PharmSciTech 1 (4), E28 (2000).

20. R. D'Souza, S. Mutalik, and N. Udupa, Drug Dev. Ind. Pharm. 32 (2), 175–184 (2006).

21. J.Y. Lee et al., Int. J. Pharm. 392 (1–2), 51–56 (2010).

22. Y.S. Lee et al., Int. J. Pharm . 383 (1–2), 244–254 (2010).

23. D.B. Shenoy, R.J. D'Souza, and N. Udupa, J. Microencapsul. 19 (4), 523–535 (2002).

24. V.R. Sinha and A. Trehan, Drug. Deliv. 15 (6), 365–372 (2008).

25. T. Nahata and T.R. Saini, Drug Dev. Ind. Pharm. 34 (7), 668–675 (2008).

26. T. Nahata and T.R. Saini, J. Microencapsul. 25 (6), 426–433 (2008).

27. C. Cui, V.C. Stevens, and S.P. Schwendeman, Vaccine 25 (3), 500–509 (2007).

28. Y.D. Liu et al., Drug Dev. Ind. Pharm. 32 (1), 85–94 (2006).

29. S. Jhunjhunwala et al., J. Control. Release 133 (3), 191–197 (2009).

30. T.R. Kumar, K. Soppimath, and S.K. Nachaegari, Curr. Pharm. Biotechnol. 7 (4), 261–276 (2006).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here